Clozapine for psychosis in Parkinson's disease

Ronald Pfeiffer, J. Kang, B. Graber, R. Hofman, J. Wilson

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa-induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5-25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa-induced psychosis who do not respond to more conservative measures.

Original languageEnglish (US)
Pages (from-to)239-242
Number of pages4
JournalMovement Disorders
Volume5
Issue number3
StatePublished - 1990
Externally publishedYes

Fingerprint

Clozapine
Psychotic Disorders
Parkinson Disease
Hallucinations
Levodopa
Antipsychotic Agents

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Pfeiffer, R., Kang, J., Graber, B., Hofman, R., & Wilson, J. (1990). Clozapine for psychosis in Parkinson's disease. Movement Disorders, 5(3), 239-242.

Clozapine for psychosis in Parkinson's disease. / Pfeiffer, Ronald; Kang, J.; Graber, B.; Hofman, R.; Wilson, J.

In: Movement Disorders, Vol. 5, No. 3, 1990, p. 239-242.

Research output: Contribution to journalArticle

Pfeiffer, R, Kang, J, Graber, B, Hofman, R & Wilson, J 1990, 'Clozapine for psychosis in Parkinson's disease', Movement Disorders, vol. 5, no. 3, pp. 239-242.
Pfeiffer R, Kang J, Graber B, Hofman R, Wilson J. Clozapine for psychosis in Parkinson's disease. Movement Disorders. 1990;5(3):239-242.
Pfeiffer, Ronald ; Kang, J. ; Graber, B. ; Hofman, R. ; Wilson, J. / Clozapine for psychosis in Parkinson's disease. In: Movement Disorders. 1990 ; Vol. 5, No. 3. pp. 239-242.
@article{20cc1b1982c14dacbdf9813d8f1b0062,
title = "Clozapine for psychosis in Parkinson's disease",
abstract = "The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa-induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5-25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa-induced psychosis who do not respond to more conservative measures.",
author = "Ronald Pfeiffer and J. Kang and B. Graber and R. Hofman and J. Wilson",
year = "1990",
language = "English (US)",
volume = "5",
pages = "239--242",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Clozapine for psychosis in Parkinson's disease

AU - Pfeiffer, Ronald

AU - Kang, J.

AU - Graber, B.

AU - Hofman, R.

AU - Wilson, J.

PY - 1990

Y1 - 1990

N2 - The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa-induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5-25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa-induced psychosis who do not respond to more conservative measures.

AB - The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa-induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5-25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa-induced psychosis who do not respond to more conservative measures.

UR - http://www.scopus.com/inward/record.url?scp=0025113382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025113382&partnerID=8YFLogxK

M3 - Article

C2 - 2388641

AN - SCOPUS:0025113382

VL - 5

SP - 239

EP - 242

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 3

ER -